Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound

A Study to Evaluate the Safety and Feasibility of Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agents in the Treatment of Brain Tumours With Doxorubicin

The purpose of this study is to evaluate the safety of BBB disruption using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent to increase the accumulation of doxorubicin in brain tumours and the adjacent brain using the ExAblate Transcranial system (220 kHz). Data will be collected to establish the basic safety of this type of treatment as the basis for later studies to evaluate its clinical efficacy.

Study Overview

• Status: Active, not recruiting
• Conditions: Brain Tumor
• Intervention / Treatment: Device: Transcranial ExABlate

• Study Type: Interventional
• Enrollment (Anticipated): 10
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M4N 3M5
      • SunnyBrook Health Sciences Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Men or women.
• Age between 18 and 70 years, inclusive.
• Able and willing to give informed consent.
• Size of the targeted portion of the tumour (i.e. prescribed ROT) is less than 2.5 cm in diameter (16 cm3). The non-targeted tumour tissue may exceed the targeted volume.
• Karnofsky rating 70-100
• ASA score 1-3.
• Able to communicate sensations during the ExAblate MRgFUS procedure.
• Able to attend all study visits (i.e., life expectancy of at least 3 months).
• At least 14 days passed since last brain surgery.

Exclusion Criteria:

• The sonication pathway to the tumour involves:

  i. More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp ii. Clips or other metallic implanted objects in the skull or the brain, except shunts

• The subject presents with symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, and papilledema)

• Cardiac disease or unstable hemodynamics including:

  i. Documented myocardial infarction within six months of enrolment ii. Unstable angina on medication iii. Congestive heart failure iv. Left ventricular ejection fraction below the lower limit of normal v. History of a hemodynamically unstable cardiac arrythmia vi. Cardiac pacemaker

• Severe hypertension (diastolic BP > 100 on medication)
• Anti-coagulant therapy, or medications known to increase risk of hemorrhage, (e.g.:ASA, non-steroidal anti-inflammatory drugs (NSAIDs), statins)
• History of a bleeding disorder, coagulopathy or with a history of spontaneous tumour hemorrhage
• Abnormal level of platelets (< 100000), PT (>14) or PTT (>36), and INR > 1.3
• Documented cerebral infarction within the past 12 months
• TIA in the last 1 month
• Cerebral or systemic vasculopathy
• Insulin-dependent diabetes mellitus
• Immunosuppression (corticosteroids to prevent/treat brain edema are permitted)
• Known sensitivity to gadolinium-DTPA
• Contraindications to MRI such as non-MRI-compatible implanted devices
• Large subjects not fitting comfortably into the MRI scanner (generally >250 lbs)
• Difficulty lying supine and still for up to 4 hours in the MRI unit or claustrophobia
• Untreated, uncontrolled sleep apnea
• Positive pregnancy test (for pre-menopausal women)
• Known life-threatening systemic disease
• Severely impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2 and/or on dialysis
• Right to left or bi-directional cardiac shunt
• Previous full course of doxorubicin chemotherapy
• Allergy to eggs or egg products

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Transcranial ExAblate; MR Guided Focused Ultrasound	Device: Transcranial ExABlate; MR Guided Focused Ultrasound; Other Names: ExAblate; TcMRgFUS

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Device and Procedure related adverse events	To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate transcranial treatment	At the time of ExAblate transcranial procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Severity of Device and Procedure related adverse events	To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate transcranial treatment	At the time of ExAblate transcranial procedure

Collaborators and Investigators

• Sponsor: InSightec

Publications and helpful links

General Publications

• Mainprize T, Lipsman N, Huang Y, Meng Y, Bethune A, Ironside S, Heyn C, Alkins R, Trudeau M, Sahgal A, Perry J, Hynynen K. Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study. Sci Rep. 2019 Jan 23;9(1):321. doi: 10.1038/s41598-018-36340-0.

Study record dates

Study Major Dates

• Study Start: October 1, 2014
• Primary Completion (Anticipated): December 1, 2021
• Study Completion (Anticipated): July 1, 2022

Study Registration Dates

• First Submitted: January 12, 2015
• First Submitted That Met QC Criteria: January 16, 2015
• First Posted (Estimate): January 22, 2015

Study Record Updates

• Last Update Posted (Actual): September 8, 2021
• Last Update Submitted That Met QC Criteria: September 7, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neoplasms; Neoplasms by Site; Central Nervous System Neoplasms; Nervous System Neoplasms; Brain Neoplasms
• Other Study ID Numbers: BBB001; 215600 (Other Identifier: Health Canada)